Şahin Ö.Yeşil A.Şenateş E.Akdoğan M.F.Konür S.Erdem E.Dal M.S.2024-04-242024-04-2420130393-6384https://hdl.handle.net/11468/24875Background: Probiotics are used in combinations of H. pylori eradication regimens with variable results. Many strains tested had shown positive effects on side effect profiles. However, a clear effect on eradication rate is studied thoroughly. We aimed to investigate the beneficial effect of a synbiotic combination in clarithromycin-based triple eradication therapy. Methods: Ninety-two patients who were infected with H. pylori (confirmed via endoscopic biopsy) were randomized into two groups: those undergoing standard triple treatment (control group (rabeprozol plus amoksisilin plus clarithromycin bid) n=49) and those receiving symbiotic (triple plus symbiotic bid group n=43). The symbiotic product contained lactobacillus, bifidobacterium and enterococcus. The 13C-breath test was performed at least 6 weeks after completing both therapy regimens. Results: In the synbiotic group, 3 of the patients complained of metallic taste (7.0%), 1 complained of diarrhea (2.3%), 3 had nausea (7.0%), 2 had gas (4.7%), 3 experienced vomiting (7.0%) and 1 had constipation (2.3%). In the control group, 3 of the patients experienced a metallic taste (6.3%), 7 had diarrhea (14.6%), 5 had nausea (10.4%), 3 had intestinal bloating (6.3%), 3 experienced vomiting (6.3%) and 1 had constipation (2.1%). There was no significant difference between the two groups. However, side effect intensity and eradication rates were significant different between the groups (p<0.05). The eradication rate in the synbiotic group was 88.4%, while it was 68.8% in the control group (p<0.05). Conclusion: The addition of synbiotic to triple therapy decreases the rate of antibiotic-related side effects. It also increases H. pylori eradication rates in clarithromycin-based triple therapy.eninfo:eu-repo/semantics/closedAccessBifidobacteriaEradicationHelicobacter PyloriLactobacillusProbioticsSynbioticsArticle2935695732-s2.0-84886065162N/A